AtriCure beats the Street during Q4, analysts predict ‘growth acceleration’

Share

AtriClip Pro-V AtriCure research

The AtriClip Pro-V [Image courtesy of AtriCure]

AtriCure (Nasdaq: ATRC) — an innovator in treatments for atrial fibrillation and left atrial appendage management — is enjoying a rise in its stock value today after releasing results that beat the Street.

Mason, Ohio–based AtriCure’s stock was up 67 cents per share, or 3.7%, closing at $18.99. The company reported yesterday evening that it revenue for the quarter ended Dec. 31 was up nearly 12% year-over-year, to $46.1 million. Analyst polled by Yahoo! Finance had predicted $45.4 million in revenue.

Get the full story on our sister site MassDevice. 

Inside Hologic's evolving definition of women's healthcare

textadimage Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.

At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!

REGISTER NOW

Use code WOMENSHEALTH to save an additional 10%.

Speak Your Mind

*